Abstract: ［Abstract］ Objective〖HTSS〗〓To evaluate the effect of Liraglutide combined with insulin glargine on curative effect and islet function among type 2 diabetes mellitus population with obesity.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓ixty type 2 diabetes mellitus patients with obesity were randomly divided into trial group and control group with 30 patients in each group.Both groups received diet and exercise education and oral dimethyldiguanide treatment.Control group was given insulin glargine hypodermic injection whereas trial group had both Liraglutide and insulin glargine hypodermic injection for 12 weeks. Body mass index(BMI),fasting bloodglucose(FBG), 2hour postprandial blood glucose(2 hPG), glycated hemoglobin(HbA1c), total cholesterol(TC), triglyceride(TG),insulin resistance index(HomaIR) and side effects were compared before and after treatment.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓Compared with that before treatment, both groups showed a significant decrease of BMI, FBG, 2 hPG, HbA1c, TC,T G and HomaIR（P＜005) with a more significant decrease in trial group. After treatment, the above indicators in the observation group were lower than those in the control group, and the difference was statistically significant（P＜005）.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Liraglutide combined with insulin glargine has good therapeutic effect on obesity patients with type 2 diabetes mellitus. It can significantly improve the metabolism of glucose and lipid, reduce weight, and improve the function of islet cells in diabetic patients. It is worthy of clinical promotion.

Key words: diabetes mellitus, type 2, obesity, islet function, liraglutide